SOLICITATION NOTICE
B -- Development and Production of Parenteral Dosage Forms for Clinical Trials
- Notice Date
- 4/30/2008
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852, UNITED STATES
- ZIP Code
- 20852
- Solicitation Number
- N02-CM-77021-39
- Response Due
- 5/6/2008 3:00:00 PM
- Point of Contact
- Theresa H. Shroff,, Phone: (301) 228-4223, MaryAnne - Golling,, Phone: (301) 228-4215
- E-Mail Address
-
ts144t@nih.gov, mg345x@nih.gov
- Description
- Amendment No.: 2 OFFICE OF ACQUISITIONS NATIONAL CANCER INSTITUTE REQUEST FOR PROPOSAL NUMBER: N02-CM-77021-39 Amendment No.: 2 Date of Issuance: April 30, 2008 The above numbered Request For Proposal (RFP) is amended as set forth below. The hour and date specified for receipt of Offerors is changed to May 13, 2008, 3:00 pm local time. Offerors MUST acknowledge receipt of the amendment prior to the hour and the date specified in the solicitation or as amended, by separate letter, telegram, or Electronic Mail which includes a reference to the RFP and Amendment number(s). For your convenience, the Proposal Intent Response Form is provided in SECTION J - List of Attachments of this RFP, for this purpose. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERORS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. This Amendment revises the RFP as stated below: Page 4: ARTICLE B.2. Estimated Cost and Fixed Fee - is amended as follows: b. The fixed fee for the Base Period of this contract is $. The fixed fee shall be paid in installments based on the percentage of completion of work, as determined by the Contracting Officer. Payment shall be subject to the withholding provisions of the clauses ALLOWABLE COST AND PAYMENT and FIXED FEE referenced in the General Clause Listing in Part II, ARTICLE I.1. of this contract. Payment of fixed fee shall not be made in less than monthly increments. Page 25: Section I.2., Authorized Substitutions of Clauses - is amended to delete the following: Alternate 1 of FAR Clause 52.233-1, Disputes, is hereby deleted. Page 33: Section J - List of Attachments - is amended to delete the following: Attachment 15, Disclosure of Lobbying Activities, OMB Form SF-LLL, is hereby deleted as this attachment is a duplicate of Attachment 11. Page 70 13. Proposer's Annual Financial Report - is amended to delete the following: A copy of the organization's most recent annual report must be submitted as part of the business proposal. 15: Travel Costs/Travel Policy - is amended to delete the following: One copy of the offeror's (and any proposed subcontractor's) written travel policy shall be included in the business proposal (original only). If an offeror (or any proposed subcontractor) does not have a written travel policy, the offeror shall so state. Page 72 2. Mandatory Evaluation Criteria - is amended to include the following: The Contractor SHALL show proof (FDA form 483) of routine FDA inspection(s) within the last two years. This requirement shall be met at the time of proposal submission.
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=1f53b1f59bd99a60118ba542193cdd36&tab=core&_cview=1)
- Record
- SN01564294-W 20080502/080430222111-d50a0cad9542c2d48ac267b0ee1b97b3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |